Properties (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:Japan
gptkb:South_Korea gptkb:United_States |
| gptkbp:chemicalFormula |
C10H10N2O5S
phenolic compound |
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:compatibleWith |
not applicable
|
| gptkbp:established |
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
|
| https://www.w3.org/2000/01/rdf-schema#label |
edaravone
|
| gptkbp:isATypeOf |
251202-72-7
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
2015
|
| gptkbp:marketedAs |
gptkb:Radicava
|
| gptkbp:numberOfStudents |
4 to 6 hours
|
| gptkbp:operates_in |
N06BX12
|
| gptkbp:regulatoryBody |
approximately 90%
|
| gptkbp:route |
intravenous
|
| gptkbp:sideEffect |
anemia
headache nausea dermatitis contusion hypersensitivity reaction asthenia |
| gptkbp:triggerType |
scavenges free radicals
|
| gptkbp:usedFor |
amyotrophic lateral sclerosis
acute ischemic stroke |